Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
17 October 2013Website:
http://www.admabiologics.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | 2 min agoDividend
Analysts recommendations
Institutional Ownership
Included in screeners
ADMA Latest News
In the most recent trading session, Adma Biologics (ADMA) closed at $19.50, indicating a -1.37% shift from the previous trading day.
ADMA Biologics reported $107.2 million in Q2 2024 revenue, a 78% year-over-year increase, with ASCENIV being the primary growth driver. ASCENIV now contributes over 50% of ADMA's total revenue, with significant market potential in treating refractory immunodeficient patients. ASCENIV's unique formulation and potential market penetration could drive peak annual sales over $1 billion, though technological advancements and existing competition pose risks.
Adma Biologics (ADMA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
In the closing of the recent trading day, Adma Biologics (ADMA) stood at $19.44, denoting a -0.26% change from the preceding trading day.
ADMA stock surges 76.2% in three months on strong performance and high growth prospects. It recently hit its 52-week high with more room for growth.
RAMSEY, N.J. and BOCA RATON, Fla., Sept. 17, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced it will join the S&P SmallCap 600 index, effective prior to the open of trading on Monday, September 23, 2024. The S&P SmallCap 600 seeks to measure the small-cap segment of the U.S. equity market.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Adma Biologics (ADMA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here is how Adma Biologics (ADMA) and CareDx (CDNA) have performed compared to their sector so far this year.
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
What type of business is ADMA Biologics?
ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
What sector is ADMA Biologics in?
ADMA Biologics is in the Healthcare sector
What industry is ADMA Biologics in?
ADMA Biologics is in the Biotechnology industry
What country is ADMA Biologics from?
ADMA Biologics is headquartered in United States
When did ADMA Biologics go public?
ADMA Biologics initial public offering (IPO) was on 17 October 2013
What is ADMA Biologics website?
https://www.admabiologics.com
Is ADMA Biologics in the S&P 500?
No, ADMA Biologics is not included in the S&P 500 index
Is ADMA Biologics in the NASDAQ 100?
No, ADMA Biologics is not included in the NASDAQ 100 index
Is ADMA Biologics in the Dow Jones?
No, ADMA Biologics is not included in the Dow Jones index
When was ADMA Biologics the previous earnings report?
No data
When does ADMA Biologics earnings report?
The next expected earnings date for ADMA Biologics is 08 November 2024